Cargando…
New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents
FDA approvals for hematologic malignancies from 2016 to 2017 can be grouped in three themes: personalized small molecules, immunotherapies, and new formulations or modes of delivery for conventional agents. The unique profiles of these drugs, including that of CAR-T cell therapy, are summarized.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333553/ |
| _version_ | 1783387567751692288 |
|---|---|
| author | Harvey, R. Donald |
| author_facet | Harvey, R. Donald |
| author_sort | Harvey, R. Donald |
| collection | PubMed |
| description | FDA approvals for hematologic malignancies from 2016 to 2017 can be grouped in three themes: personalized small molecules, immunotherapies, and new formulations or modes of delivery for conventional agents. The unique profiles of these drugs, including that of CAR-T cell therapy, are summarized. |
| format | Online Article Text |
| id | pubmed-6333553 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Harborside Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-63335532019-02-04 New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents Harvey, R. Donald J Adv Pract Oncol Meeting Reports FDA approvals for hematologic malignancies from 2016 to 2017 can be grouped in three themes: personalized small molecules, immunotherapies, and new formulations or modes of delivery for conventional agents. The unique profiles of these drugs, including that of CAR-T cell therapy, are summarized. Harborside Press 2018-04 2018-04-01 /pmc/articles/PMC6333553/ Text en Copyright © 2018, Harborside Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and is for non-commercial purposes. |
| spellingShingle | Meeting Reports Harvey, R. Donald New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents |
| title | New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents |
| title_full | New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents |
| title_fullStr | New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents |
| title_full_unstemmed | New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents |
| title_short | New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents |
| title_sort | new drug updates in hematologic malignancies: car-t, targeted therapeutics, and other agents |
| topic | Meeting Reports |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333553/ |
| work_keys_str_mv | AT harveyrdonald newdrugupdatesinhematologicmalignanciescarttargetedtherapeuticsandotheragents |